05:18 AM EDT, 06/14/2024 (MT Newswires) -- Ultragenyx Pharmaceutical ( RARE ) said late Thursday it has priced an underwritten public offering of 7.4 million common shares at $39 per share for expected gross proceeds of about $350 million.

The company is offering pre-funded warrants, in lieu of common stock to certain investors, to purchase about 1.5 million shares at $38.999 per warrant.

Ultragenyx gave the underwriters a 30-day option to buy up to 1.3 million additional shares.

Price: 42.93, Change: -0.19, Percent Change: -0.44